Identifying new drugs to prevent dangerous heart rhythms
Official title: A full spectrum rational approach to identify antiarrhythmic agents targeting IKs Channels
Funded at State University New York Stony Brook · NIH-11077368 · Data updated 2026-11-12
This study is looking for new medications to help people with Acquired Long Q-T Syndrome (aLQTS) by finding ways to make their heart's electrical activity safer and shorter, which could lead to better treatment options with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project start | July 1, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $683,001 |
| NIH project number | 5R01HL166628-03 |
| Project ID | NIH-11077368 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of developing aLQTS or those currently taking medications that may induce this condition.
✕Less likely to help
Patients who do not have aLQTS or are not on medications that affect heart rhythm may not benefit from this research.
What this research studies
This research focuses on Acquired Long Q-T Syndrome (aLQTS), a condition that can lead to life-threatening heart arrhythmias due to prolonged electrical activity in the heart. The team aims to develop new medications that can shorten this electrical activity by targeting specific potassium channels (IKs) in the heart. By using a systematic approach called Full Spectrum Rational Drug Design, they will explore how certain compounds can enhance the function of these channels, potentially allowing for safer use of existing medications that currently have dose limitations due to their side effects. Patients may benefit from safer treatment options for conditions that can induce aLQTS.
Why it matters
Potential benefit: If successful, this research could lead to safer antiarrhythmic drugs that reduce the risk of sudden cardiac events.
How similar studies have gone: Previous research has shown promise in targeting potassium channels for arrhythmia treatment, indicating that this approach may yield beneficial results.
Where this research is happening
-
State University New York Stony Brook
Stony Brook, United States Active
Researchers
- Principal investigator: Lin, Richard Z — State University New York Stony Brook
- Study coordinator: Lin, Richard Z
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.